Flucloxacillin Is a Weak Inducer of CYP3A4 in Healthy Adults and 3D Spheroid of Primary Human Hepatocytes

Flucloxacillin is a widely used antibiotic. It is an agonist to the nuclear receptor PXR that regulates the expression of cytochrome P450 (CYP) enzymes. Treatment with flucloxacillin reduces warfarin efficacy and plasma concentrations of tacrolimus, voriconazole, and repaglinide. We conducted a translational study to investigate if flucloxacillin induces CYP enzymes. We also investigated if flucloxacillin induces its own metabolism as an autoinducer. We performed a randomized, unblinded, two‐period, cross‐over, clinical pharmacokinetic cocktail study. Twelve healthy adults completed the study. They ingested 1 g flucloxacillin 3 times daily for 31 days, and we assessed the full pharmacokinetics of the Basel cocktail drugs on days 0, 10, and 28, and plasma concentrations of flucloxacillin on days 0, 9, and 27. The 3D spheroid of primary human hepatocytes (PHHs) were exposed to flucloxacillin (concentration range: 0.15–250 μM) for 96 hours. Induction of mRNA expression, protein abundance, and enzyme activity of CYP enzymes were assessed. Flucloxacillin treatment reduced the metabolic ratio of midazolam (CYP3A4), (geometric mean ratio (GMR) 10 days (95% confidence interval (CI)): 0.75 (0.64–0.89)) and (GMR 28 days (95% CI): 0.72 (0.62–0.85)). Plasma concentrations of flucloxacillin did not change during 27 days of treatment. Flucloxacillin caused concentration‐dependent induction of CYP3A4 and CYP2B6 (mRNA, protein, and activity), CYP2C9 (mRNA and protein), CYP2C19 (mRNA and activity), and CYP2D6 (activity) in 3D spheroid PHH. In conclusion, flucloxacillin is a weak inducer of CYP3A4, which may lead to clinically relevant drug–drug interactions for some narrow therapeutic range drugs that are substrates of CYP3A4.

[1]  A. Pottegård,et al.  Dicloxacillin‐warfarin drug–drug interaction—A register‐based study and in vitro investigations in 3D spheroid primary human hepatocytes , 2023, British journal of clinical pharmacology.

[2]  Xiangyun Meng,et al.  Activation/Inactivation of Anticancer Drugs by CYP3A4: Influencing Factors for Personalized Cancer Therapy , 2023, Drug Metabolism And Disposition.

[3]  M. Ingelman-Sundberg,et al.  3D Spheroid Primary Human Hepatocytes for Prediction of Cytochrome P450 and Drug Transporter Induction , 2022, bioRxiv.

[4]  A. Pottegård,et al.  Drug metabolism and drug transport of the 100 most prescribed oral drugs , 2022, Basic & clinical pharmacology & toxicology.

[5]  T. Stage,et al.  Tutorial: Statistical analysis and reporting of clinical pharmacokinetic studies , 2022, Clinical and translational science.

[6]  P. Annaert,et al.  Concomitant Treatment with Voriconazole and Flucloxacillin: A Combination to Avoid , 2021, Antibiotics.

[7]  M. Bue,et al.  Flucloxacillin bone and soft tissue concentrations assessed by microdialysis in pigs after intravenous and oral administration , 2021, Bone & joint research.

[8]  D. Touw,et al.  Flucloxacillin decreases tacrolimus blood trough levels: a single-center retrospective cohort study , 2020, European Journal of Clinical Pharmacology.

[9]  Sabine U. Vorrink,et al.  Clinically Relevant Cytochrome P450 3A4 Induction Mechanisms and Drug Screening in Three‐Dimensional Spheroid Cultures of Primary Human Hepatocytes , 2020, Clinical pharmacology and therapeutics.

[10]  P. B. Jensen,et al.  Ischemic Stroke and Systemic Embolism in Warfarin Users With Atrial Fibrillation or Heart Valve Replacement Exposed to Dicloxacillin or Flucloxacillin , 2020, Clinical pharmacology and therapeutics.

[11]  Diane D. Wang,et al.  Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug–Drug Interaction Studies , 2020, Clinical Pharmacokinetics.

[12]  E. Slater,et al.  Cytochrome. , 2020, British Medical Bulletin.

[13]  J. V. van Dissel,et al.  The simplified oral flucloxacillin absorption test: an accurate method to identify patients with inadequate oral flucloxacillin absorption. , 2019, The Netherlands journal of medicine.

[14]  A. Pottegård,et al.  The Effect of Flucloxacillin on Warfarin Anticoagulation: A Swedish Register-Based Nationwide Cohort Study , 2019, Thrombosis and Haemostasis.

[15]  Xue Pan,et al.  A new similarity method for assessment of pharmacokinetic interaction between flucloxacillin and midazolam. , 2019, Pharmazie.

[16]  A. D. Rodrigues,et al.  Guidance for Rifampin and Midazolam Dosing Protocols To Study Intestinal and Hepatic Cytochrome P450 (CYP) 3A4 Induction and De-induction , 2019, The AAPS Journal.

[17]  N. Vermeulen,et al.  Characterization of kinetics of human cytochrome P450s involved in bioactivation of flucloxacillin: inhibition of CYP3A‐catalysed hydroxylation by sulfaphenazole , 2018, British journal of pharmacology.

[18]  A. Pottegård,et al.  Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro , 2018, British journal of clinical pharmacology.

[19]  J. G. van der Hoeven,et al.  Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations , 2017, Antimicrobial Agents and Chemotherapy.

[20]  Benjamin Berger,et al.  Comparison of Liver Cell Models Using the Basel Phenotyping Cocktail , 2016, Front. Pharmacol..

[21]  Taosheng Chen,et al.  PXR variants: the impact on drug metabolism and therapeutic responses , 2016, Acta pharmaceutica Sinica. B.

[22]  M. Ingelman-Sundberg,et al.  Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease , 2016, Scientific Reports.

[23]  A. Pottegård,et al.  Change in International Normalized Ratio Among Patients Treated With Dicloxacillin and Vitamin K Antagonists. , 2015, JAMA.

[24]  S. Krähenbühl,et al.  Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study , 2015, Clinical Pharmacokinetics.

[25]  S. Krähenbühl,et al.  The Basel Cocktail for Simultaneous Phenotyping of Human Cytochrome P450 Isoforms in Plasma, Saliva and Dried Blood Spots , 2014, Clinical Pharmacokinetics.

[26]  H. Watanabe,et al.  Chronological Effects of Rifampicin Discontinuation on Cytochrome P450 Activity in Healthy Japanese Volunteers, Using the Cocktail Method , 2013, Clinical pharmacology and therapeutics.

[27]  Zhijun Wang,et al.  PXR polymorphisms and their impact on pharmacokinetics/pharmacodynamics of repaglinide in healthy Chinese volunteers , 2013, European Journal of Clinical Pharmacology.

[28]  H. Park,et al.  Treatment Duration for Uncomplicated Staphylococcus aureus Bacteremia To Prevent Relapse: Analysis of a Prospective Observational Cohort Study , 2012, Antimicrobial Agents and Chemotherapy.

[29]  Thomas M Polasek,et al.  Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment. , 2011, British journal of clinical pharmacology.

[30]  C Gibson,et al.  Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model‐Based Approaches to Drug–Drug Interaction Trial Design , 2011, Clinical pharmacology and therapeutics.

[31]  M. Hebert,et al.  CYP2D6 Mediates 4-Hydroxylation of Clonidine In Vitro: Implication for Pregnancy-Induced Changes in Clonidine Clearance , 2010, Drug Metabolism and Disposition.

[32]  W. Daniel,et al.  The relative contribution of human cytochrome P450 isoforms to the four caffeine oxidation pathways: an in vitro comparative study with cDNA-expressed P450s including CYP2C isoforms. , 2008, Biochemical pharmacology.

[33]  Magnus Ingelman-Sundberg,et al.  Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. , 2007, Pharmacology & therapeutics.

[34]  Toshiyuki Shimizu,et al.  AUTOINDUCTION OF MKC-963 [(R)-1-(1-CYCLOHEXYLETHYLAMINO)-4-PHENYLPHTHALAZINE] METABOLISM IN HEALTHY VOLUNTEERS AND ITS RETROSPECTIVE EVALUATION USING PRIMARY HUMAN HEPATOCYTES AND CDNA-EXPRESSED ENZYMES , 2006, Drug Metabolism and Disposition.

[35]  C. Rayner,et al.  Antibiotics currently used in the treatment of infections caused by Staphylococcus aureus , 2005, Internal medicine journal.

[36]  L. Moore,et al.  Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. , 2001, Molecular pharmacology.

[37]  P. Worboys,et al.  Abstracts Accepted for American Conference on Pharmacometrics 2015 (ACoP6) , 2015, Journal of Pharmacokinetics and Pharmacodynamics.

[38]  Guideline on the Investigation of Drug Interactions , 2010 .

[39]  H. Mattie,et al.  Active metabolites of isoxazolylpencillins in humans. , 1976, Antimicrobial agents and chemotherapy.

[40]  M. Eriksson,et al.  Influence of diarrhea on the oral absorption of penicillin V and ampicillin in children. , 1975, Scandinavian journal of infectious diseases.